Q3 net sales grew +4% (cc ¹, +4% USD), with core operating income ¹ +10% (cc, +11% USD) Sales growth driven by priorit ...
MRI disease activity significantly reduced with remibrutinib vs. teriflunomide in two trials, including reductions in T2 lesion activity by 65% and 70%, and Gd+ T1 lesions by 66% across both trials¹ ...
“The clinically meaningful overall survival benefit observed in NATALEE underscores Kisqali as a standard of care for eligible patients and its foundational role in early breast cancer treatment,” ...
About Novartis Neuroscience Neurological diseases are deeply personal, affecting people of any age, from newborns to seniors, often striking in the prime of life. In multiple sclerosis (MS), Novartis ...
ノバルティス ファーマ株式会社（本社：東京都港区、代表取締役社長：ジョンポール・プリシーノ、以下「ノバルティス ファーマ」）は、患者さんやご家族と医療従事者が医療に関する ...
East Hanover, October 7, 2026 – Novartis announced today that the U.S. Food and Drug Administration (FDA) approved Rhapsido ® (remibrutinib), an oral, highly selective Bruton’s tyrosine kinase ...
バーゼル、2026年4月24日 — ノバルティスは本日、世界保健機関（WHO）が体重2～5キログラムの新生児および低月齢乳児のために特別に開発された、世界初かつ唯一の抗マラリア薬であるCoartem ...
Why Novartis: Helping people with disease and their families takes more than innovative science. It takes a community of smart, passionate people like you. Collaborating, supporting and inspiring each ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results